Myeloma Panel by Flow Cytometry, EDTA Bone Marrow**

The expressions of CD38, CD56, CD19, and CD45 protein markers help identify the composition and function of cells within the bone marrow. The "Myeloma panel by flow cytometry, Bone marrow" test involves analyzing specific parameters in bone marrow samples using flow cytometry. The clinical utility of this test lies in the evaluation of various markers, including CD38, CD56, CD19, CD45, Kappa, and Lambda. By measuring these six parameters, the test helps in the diagnosis and monitoring of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. CD38 is a marker commonly expressed on myeloma cells, while CD56 may indicate an aggressive form of the disease. CD19 and CD45 help identify other cell types present in the sample, and Kappa and Lambda are used to assess the presence of abnormal plasma cells and determine the light chain restriction. This comprehensive panel aids healthcare professionals in accurate disease detection, classification, and treatment planning for patients with multiple myeloma.